Literature DB >> 21080187

Has drug therapy changed the natural history of Parkinson's disease?

C E Clarke1.   

Abstract

This narrative review examines the effects of drug therapy on the natural history of Parkinson's disease. In terms of modifying the underlying disease process, it is possible that immediate therapy, rather than deferred treatment, can have a positive effect on the underlying disease process. However, it is unlikely that drug therapy has changed mortality from the condition and there is no evidence that it can delay the onset of non-motor features such as dementia and falls. The beneficial effects of drug therapy on the motor symptoms of Parkinson's disease are unquestionable, but these are at the expense of short-term dopaminergic side effects, long-term motor complications, and impulse control disorders. Major questions remain regarding which initial therapeutic approach should be taken which may possibly be answered by the ongoing PD MED trial. The beneficial effects of drug therapy on the motor features of Parkinson's disease have had a fundamental impact on the suffering of patients. The mainstay of these therapies continues to be levodopa, although it is now used at lower doses than in the past and in combination with other drug classes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080187     DOI: 10.1007/s00415-010-5716-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  14 in total

1.  Mortality from Parkinson's disease.

Authors:  C E CLarke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

2.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Authors: 
Journal:  Arch Neurol       Date:  2004-04

3.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.

Authors:  Anthony H V Schapira; Stefan Albrecht; Paolo Barone; Cynthia L Comella; Michael P McDermott; Yoshikuni Mizuno; Werner Poewe; Olivier Rascol; Kenneth Marek
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.

Authors:  Natalie J Ives; Rebecca L Stowe; Joanna Marro; Carl Counsell; Angus Macleod; Carl E Clarke; Richard Gray; Keith Wheatley
Journal:  BMJ       Date:  2004-08-13

Review 7.  Dopamine agonist therapy in early Parkinson's disease.

Authors:  R L Stowe; N J Ives; C Clarke; J van Hilten; J Ferreira; R J Hawker; L Shah; K Wheatley; R Gray
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

8.  Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

Authors:  Carl E Clarke
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

9.  Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Authors:  Ira Shoulson; David Oakes; Stanley Fahn; Anthony Lang; J William Langston; Peter LeWitt; C Warren Olanow; John B Penney; Caroline Tanner; Karl Kieburtz; Alice Rudolph
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

10.  Mortality from Parkinson's disease in England and Wales 1921-89.

Authors:  C E Clarke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

View more
  5 in total

Review 1.  An update on the diagnosis and treatment of Parkinson disease.

Authors:  Philippe Rizek; Niraj Kumar; Mandar S Jog
Journal:  CMAJ       Date:  2016-05-24       Impact factor: 8.262

Review 2.  Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

Authors:  Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky
Journal:  eNeurologicalSci       Date:  2017-07-02

Review 3.  Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review.

Authors:  Shazia Mirza; Umar Yazdani; Richard Dewey Iii; Neepa Patel; Richard B Dewey; Svjetlana Miocinovic; Shilpa Chitnis
Journal:  Parkinsons Dis       Date:  2017-06-19

4.  The effect of a structured medication review on quality of life in Parkinson's disease: The study protocol.

Authors:  N G M Oonk; K L L Movig; E M Munster; K Koehorst-Ter Huurne; J van der Palen; L D A Dorresteijn
Journal:  Contemp Clin Trials Commun       Date:  2018-11-28

Review 5.  Urinary Tract Infection in Parkinson's Disease.

Authors:  Elliot Hogg; Samuel Frank; Jillian Oft; Brian Benway; Mohammad Harun Rashid; Shouri Lahiri
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.